About: Aptamer-Based Therapeutics: New Approaches to Combat Human Viral Diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Aptamer-Based Therapeutics: New Approaches to Combat Human Viral Diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Aptamer-Based Therapeutics: New Approaches to Combat Human Viral Diseases
Creator	Zhou, Jiehua Shum, Ka-To Rossi, John
Source	Medline; PMC
abstract	Viruses replicate inside the cells of an organism and continuously evolve to contend with an ever-changing environment. Many life-threatening diseases, such as AIDS, SARS, hepatitis and some cancers, are caused by viruses. Because viruses have small genome sizes and high mutability, there is currently a lack of and an urgent need for effective treatment for many viral pathogens. One approach that has recently received much attention is aptamer-based therapeutics. Aptamer technology has high target specificity and versatility, i.e., any viral proteins could potentially be targeted. Consequently, new aptamer-based therapeutics have the potential to lead a revolution in the development of anti-infective drugs. Additionally, aptamers can potentially bind any targets and any pathogen that is theoretically amenable to rapid targeting, making aptamers invaluable tools for treating a wide range of diseases. This review will provide a broad, comprehensive overview of viral therapies that use aptamers. The aptamer selection process will be described, followed by an explanation of the potential for treating virus infection by aptamers. Recent progress and prospective use of aptamers against a large variety of human viruses, such as HIV-1, HCV, HBV, SCoV, Rabies virus, HPV, HSV and influenza virus, with particular focus on clinical development of aptamers will also be described. Finally, we will discuss the challenges of advancing antiviral aptamer therapeutics and prospects for future success.
has issue date	2013-11-25(xsd:dateTime)
bibo:doi	10.3390/ph6121507
bibo:pmid	24287493
has license	cc-by
sha1sum (hex)	f7740a58d95fb643e40af517b3da5a3d925edb50
schema:url	https://doi.org/10.3390/ph6121507
resource representing a document's title	Aptamer-Based Therapeutics: New Approaches to Combat Human Viral Diseases
has PubMed Central identifier	PMC3873675
has PubMed identifier	24287493
schema:publication	Pharmaceuticals (Basel)
resource representing a document's body	covid:f7740a58d95fb643e40af517b3da5a3d925edb50#body_text
is schema:about of	named entity 'NEW' named entity 'GENOME SIZES' named entity 'AIDS' named entity 'HSV' named entity 'RABIES VIRUS' named entity 'HBV' named entity 'BASED' named entity 'BIND' named entity 'SUCCESS' named entity 'PROVIDE' named entity 'DISCUSS' named entity 'LIFE' named entity 'VARIETY' named entity 'EVOLVE' named entity 'SELECTION PROCESS' named entity 'ENVIRONMENT' named entity 'TREATING' named entity 'PROSPECTIVE' named entity 'VIRUS INFECTION' named entity 'CHALLENGES' named entity 'CAUSED BY' named entity 'CHANGING' named entity 'ANTIVIRAL' named entity 'TARGET' named entity 'LEAD' named entity 'INFLUENZA VIRUS' named entity 'BASED' named entity 'TOOLS' named entity 'DESCRIBED' named entity 'CELLS' named entity 'SARS' named entity 'REVIEW' named entity 'URGENT' named entity 'APTAMER' named entity 'THERAPEUTICS' named entity 'VIRAL DISEASES' named entity 'APTAMER' named entity 'HUMAN' named entity 'APPROACHES' named entity 'EFFECTIVE' named entity 'APPROACH' named entity 'CLINICAL DEVELOPMENT' named entity 'HCV' named entity 'USE OF' named entity 'PROGRESS' named entity 'TARGETING' named entity 'THERAPEUTICS' named entity 'HIGH' named entity 'APTAMER TECHNOLOGY' named entity 'BROAD' named entity 'TARGETED' named entity 'TARGETS' named entity 'SPECIFICITY' named entity 'RECENTLY' named entity 'MUCH' named entity 'NEW' named entity 'FUTURE' named entity 'HUMAN' named entity 'DISEASES' named entity 'COMPREHENSIVE' named entity 'AMENABLE' named entity 'TREATMENT' named entity 'PARTICULAR' named entity 'EXPLANATION' named entity 'HIV-1' named entity 'NEED FOR' named entity 'VIRAL PATHOGENS' named entity 'FOCUS' named entity 'OVERVIEW' named entity 'RECENT' named entity 'CANCERS' named entity 'RAPID' named entity 'CURRENTLY' named entity 'WIDE' named entity 'RANGE' named entity 'RECEIVED' named entity 'INSIDE' named entity 'ANTI-INFECTIVE DRUGS' named entity 'REVOLUTION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software